Streptococcus pneumoniae invasive and bronchoalveolar lavage isolates in adult patients in Türkiye (2019-2025): serotype distribution, antibiotic resistance, and serotype coverage of pneumococcal vaccine - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Invasive and Bronchoalveolar Lavage Isolates of Streptococcus pneumoniae in Adult Patients in Türkiye (2019-2025): Analysis of Serotype Distribution, Antibiotic Resistance, and Pneumococcal Vaccine Coverage

  • By

  • Gülsen Hascelik

  • Cuneyt Ozakin

  • Gulsen Hazirolan

  • Ufuk Hasdemir

  • Murat Telli

  • Sabire Söhret Aydemir

  • Yasemin Ay Altintop

  • Esra Ozkaya

  • Gul Durmaz

  • Ozgen Alpay Ozbek

  • Lutfiye Oksuz

  • Deniz Bahar Akgun Karapinar

  • Hakan Uslu

  • Asuman Birinci

  • Zeynep Cizmeci

  • Betil Ozhak

  • Akgun Yaman

  • Nisel Yilmaz

  • Nezahat Akpolat

  • Candan Ozturk

  • September 18, 2026

Share

  • 1

    Streptococcus pneumoniae causes invasive and noninvasive infections, with more serious disease in older adults, immunocompromised individuals, and people with underlying conditions.

  • 2

    The paper reports that Türkiye provides the 13-valent pneumococcal conjugate vaccine free to adults aged ≥65 years and at-risk adults. The 23-valent polysaccharide vaccine is reimbursed for specified risk groups.

  • 3

    The study evaluated 462 adult pneumococcal isolates collected from January 2019 through August 2025 at 27 tertiary hospitals across 17 cities in Türkiye.

  • 4

    Serotype 3 predominated at 17.3%. Erythromycin nonsusceptibility increased from 33.3% in 2019 to 57.5% in 2025, reinforcing the need for surveillance and prudent antibiotic use.

  • 5

    Potential serotype coverage was 34.6% for the 13-valent conjugate vaccine and 47.8% for the 20-valent vaccine. The study assessed serotype coverage rather than vaccine efficacy.

Original Source(s)

Streptococcus pneumoniae invasive and bronchoalveolar lavage isolates in adult patients in Türkiye (2019-2025): serotype distribution, antibiotic resistance, and serotype coverage of pneumococcal vaccine

  • by Gülsen Hascelik, Cuneyt Ozakin, Gulsen Hazirolan, Ufuk Hasdemir, Murat Telli, Sabire Söhret Aydemir, Yasemin Ay Altintop, Esra Ozkaya, Gul Durmaz, Ozgen Alpay Ozbek, Lutfiye Oksuz, Deniz Bahar Akgun Karapinar, Hakan Uslu, Asuman Birinci, Zeynep Cizmeci, Betil Ozhak, Akgun Yaman, Nisel Yilmaz, Nezahat Akpolat, Candan Ozturk

  • September 18, 2026

Related Content

HHS Launches First Ever Department-Wide PPE Demand Forecast to Strengthen American Manufacturing

Interpreting viral severe acute respiratory infection in critically ill immunocompromised patients: phenotype, co-infections, and severity

Antibiotic self-medication and public awareness during the 2023 Gaza war: a cross-sectional investigation